Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation

American Journal of Transplantation

Volumn 6, Issue 9, 2006, Pages 2157-2163

  Canales, M ^a   Youssef, P ^a   Spong, R ^a   Ishani, A ^a   Savik, K ^a   Hertz, M ^a   Ibrahim, H N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic kidney disease; Heart lung transplantation; Long term survivors; Lung transplantation

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGING; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LUNG TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SURVIVAL TIME;

CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33746863330     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01458.x     Document Type: Article

References (46)

1. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-first official adult lung and heart-lung transplant report - 2004. J Heart Lung Transplant 2004; 23: 804-815.
2. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart lung transplantation. Kidney Int 2002; 61: 2228-2234.
3. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
4. Kunst H, Thompson D, Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: A cohort study. J Heart Lung Transplant 2004; 23: 1182-1188.
5. Broekroelofs J, Stegeman CA, Navis G, de Jong PE. Prevention of renal function loss after non-renal solid organ transplantation - How can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 1999; 14: 1841-1843.
6. Broekroelofs J, Navis G, Stegeman CA, van der Bij W, de Jong PE. Lung transplantation. Lancet 1998; 351: 1064.
7. Rocha AT, Rocha PN, Smith SR, Palmer SM. Chronic kidney disease after lung transplantation. Am J Transplant 2004; 4: 226.
8. Rocha PN, Rocha AT, Palmer SM, Davis RD, Smith SR. Acute renal failure after lung transplant: Incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005; 5: 1469-1476.
9. Canales MT, Youssef P, Spong R et al. Chronic kidney disease in long term lung transplant survivors [abstract]. Am J Transplant 2005; 5: 346.
10. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore JL. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26: 643-648.
11. Sehgal V, Radhakrishnan J, Appel GB, Valeri A, Cohen DJ. Progressive renal insufficiency following cardiac transplantation: Cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26: 193-201.
12. Lindelow B, Bergh C, Herlitz H, Waagstein F. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11: 951-957.
13. van Gelder T, Balk AHM, Zietse R, Hesse C, Mochtar B. Renal insufficiency after heart transplantation: A case-control study. Nephrol Dial Transplant 1998; 13: 2322-2326.
14. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung rejection study group. J Heart Lung Transplant 1996; 15: 1-15.
15. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
16. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratifi-cation. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266.
18. Levey AS, Bosch JP, Lewis JV, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
19. Owen WF. Patterns of care for patients with chronic kidney disease in the United States: Dying for improvement. J Am Soc Nephrol 2003; 14: S76-S80.
20. Ishani A, Ibrahim HN, Gilbertson D, Collins AJ. The impact of residual renal function on graft and patient survival rates in recipients of preemptive renal transplants. Transplantation 2003; 42: 1275-1282.
21. Broekroelofs J, Navis GJ, Stegeman CA et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Clin Transplant 2000; 69: 1624-1628.
22. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
23. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, DeFerrari G, Eisner G. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.
24. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84: 1065-1073.
25. Latouche A, Porhcer R, Chevret S. A note on including time dependent covariates in a regression model for competing risk. Biom J 2005; 47: 807-814.
26. Maurer JR, Tewari S. Surgical approaches to end-stage disease: Lung transplantation and volume reduction. Clin Chest Med 1997; 18: 367-382.
27. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
28. Goral S, Ynares C, Shyr Y, Yeoh TK, Johnson HK. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997; 16: 1106-1112.
29. Foley R, Ishani A, Ibrahim H, Collins A. Loss of kidney function in older adults: Common but limited. The Framingham Heart Study [abstract]. J Am Soc Nephrol 2005; 16: 549.
30. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantion. Am J Transplant 2006; 6: 671-679.
31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
32. Navis GJ, de Zeeuw D, de Jong PE. ACE inhibitors: Panacea for progressive renal disease [editorial]? Lancet 1997; 349: 1852-1853.
33. The GISEN group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and progression to terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
34. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
35. Wright JT, Bakris G, Grenne T et al. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421-2431.
36. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
37. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
38. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.
39. Goldberg H, Ibrahim HN, Canales MT et al. Rapamycin does not alleviate GFR decay in lung transplant recipients [abstract]. Am J Transplant 2005; 5: 345.
40. Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540-546.
41. Venuta F, De Giacomo T, Rendina EA et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004; 78: 1940-1943.
42. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522.
43. Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755-3762.
44. Groetzner J, Kur F, Spelsberg F et al. Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23: 632-638.
45. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437-1443.
46. Broekroelofs J, Stegeman CA, Navis GJ et al. Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? J Heart Lung Transplant 2000; 19: 256-262.